Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01189 (
beta-endorphin
)
21,003
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Agouti protein and
Agouti-related protein
(
Agrp
) are paracrine-signaling molecules that normally regulate pigmentation and body weight, respectively. These proteins antagonize the effects of
alpha-melanocyte-stimulating hormone
(
alpha-MSH
) and other melanocortins, and several alternatives have been proposed to explain their biochemical mechanisms of action. We have used a sensitive bioassay based on Xenopus melanophores to characterize pharmacologic properties of recombinant Agouti protein, and have directly measured its cell-surface binding to mammalian cells by use of an epitope-tagged form (HA-Agouti) that retains biologic activity. In melanophores, Agouti protein has no effect in the absence of
alpha-MSH
, but its action cannot be explained solely by inhibition of
alpha-MSH
binding. In 293T cells, expression of the Mc1r confers a specific, high-affinity binding site for HA-Agouti. Binding is inhibited by
alpha-MSH
, or by
Agrp
, which indicates that
alpha-MSH
and Agouti protein bind in a mutually exclusive way to the Mc1r, and that the similarity between Agouti protein and
Agrp
includes their binding sites. The effects of Agouti and the Mc1r in vivo have been examined in a sensitized background provided by the chinchilla (Tyrc-ch) mutation, which uncovers a phenotypic difference between overexpression of Agouti in lethal yellow (Ay/a) mice and loss of Mc1r function in recessive yellow (Mc1re/Mc1re) mice. Double and triple mutant studies indicate that a functional Mc1r is required for the pigmentary effects of Agouti, and suggest that Agouti protein can act as an agonist of the Mc1r in a way that differs from
alpha-MSH
stimulation. These results resolve questions regarding the biochemical mechanism of Agouti protein action, and provide evidence of a novel signaling mechanism whereby
alpha-MSH
and Agouti protein or
Agrp
function as independent ligands that inhibit each other's binding and transduce opposite signals through a single receptor.
...
PMID:Interaction of Agouti protein with the melanocortin 1 receptor in vitro and in vivo. 945 Sep 27
Alterations of hypothalamic neuropeptide Y(NPY) and melanocortinergic functions in diet-induced obese (DIO) C57BL/6J mice were investigated by in situ hybridization. Compared with controls, the DIO mice displayed a profound induction (approximately 40-fold) of NPY expression in the dorsomedial (DMH) and ventromedial (VMH) hypothalamic nuclei, whereas the level of NPY mRNA in the arcuate nucleus (ARC) was reduced by 44%. The expression of
pro-opiomelanocortin (POMC)
and
agouti-related protein
was not significantly altered in the ARC of obese mice. Both excess body weight gain and altered hypothalamic NPY expression were reversible. We propose that the highly induced NPY expression in DMH and/or VMH may be a contributing etiological factor for the development of obesity and leptin resistance in the DIO mice.
...
PMID:Induction of neuropeptide Y expression in dorsomedial hypothalamus of diet-induced obese mice. 985 91
Agouti-related protein
(
AGRP
) is a naturally occurring antagonist of melanocortin action that is thought to play an important role in the hypothalamic control of feeding behavior. The exact mechanism of
AGRP
and Agouti protein action has been difficult to examine, in part because of difficulties in producing homogeneous forms of these molecules that can be used for direct binding assays. In this report we describe the application of chemical protein synthesis to the construction of two novel
AGRP
variants. Examination of the biological activity of the
AGRP
variants demonstrates that a truncated variant, human
AGRP
(87-132), a 46-amino acid variant based on the carboxyl-terminal cysteine-rich domain of
AGRP
, is equipotent to an 111-amino acid variant, mouse [Leu127Pro]
AGRP
(mature
AGRP
minus its signal sequence), in its ability to dose dependently inhibit
alpha-MSH
-generated cAMP generation at the cloned melanocortin receptors. Furthermore, deletion of the amino-terminal portion of the full-length variant did not alter the MCR subtype specificity of
AGRP
(87-132). Finally, iodination of human
AGRP
(87-132) provided a useful reagent with which the binding properties of
AGRP
could be analyzed. In both conventional and photoemulsion binding studies [125I]
AGRP
(87-132) was observed only to bind to cells expressing melanocortin receptors MC3R, MC4R, and MC5R. These results demonstrate that the residues critical for receptor binding,
alpha-MSH
inhibition, and melanocortin receptor subtype specificity are all located in the carboxyl terminus of the molecule. Because [Nle4, D-Phe7] (NDP)-MSH displaces the binding of [125I]
AGRP
(87-132) to MCRs and
AGRP
(87-132) displaces the binding of [125I]NDP-MSH, we conclude that these molecules bind in a competitive fashion to melanocortin receptors.
...
PMID:Characterization of Agouti-related protein binding to melanocortin receptors. 989 20
Agouti protein and the
Agouti-related protein
(
AGRP
) are antagonists of the melanocortin-3 receptor and melanocortin-4 receptor. Both proteins contain 10 cysteines in the C-terminal domain arranged in five disulfide bonds. One possible arrangement of the disulfide bonds predicts an octapeptide loop, and the chemical properties of four residues within this loop (residues 111-114 in human
AGRP
) bear striking resemblance to those of several melanocortin peptides, including
alpha-MSH
, MT-II, and SHU-9119. We showed that cyclic synthetic octapeptides based on the sequence of this loop from Agouti protein or human
AGRP
are functional antagonists of the human melanocortin-4 receptor. All peptides had a lower affinity for the melanocortin-3 receptor than for the melanocortin-4 receptor. Substitution of serines for cysteines resulted in linear peptides which had reduced binding affinities for both receptors. Mutational analysis of human
AGRP
indicated that its C-terminal domain is functionally equivalent to the intact human
AGRP
. The RFF111-113 triplet appears to be the most critical portion of
AGRP
in determining the binding affinity for both melanocortin-3 and melanocortin-4 receptors. These data strongly suggest that the loop defined by Cys-110 and Cys-117 is critical in determining the antagonist activity of human
AGRP
. Our data provide indirect evidence for the suggestion that the Cys-110 to Cys-117 octapeptide loop of human
AGRP
mimics the conformation of
alpha-MSH
, MT-II, and SHU-9119.
...
PMID:Molecular interaction of Agouti protein and Agouti-related protein with human melanocortin receptors. 989 84
Melanocortin-4 receptor (MC4-R) density is thought to be regulated by synaptic availability of endogenous agonist,
alpha-melanocyte-stimulating hormone
(
alpha-MSH
), and also by
agouti-related protein
(
AGRP
), which acts as a competitive antagonist. As hypothalamic MC4-R have been implicated in the regulation of energy balance, we examined concentrations of
alpha-MSH
and
AGRP
in hypothalami of dietary-obese and food-restricted rats. In dietary-obese rats,
AGRP
concentrations were significantly increased by 43% (p < 0.01) above lean controls, whereas a 91% (p < 0.01) reduction was observed in food-restricted rats. Surprisingly, hypothalamic concentrations of
alpha-MSH
and its precursor peptide,
pro-opiomelanocortin (POMC)
, did not differ significantly from controls in either model. In conclusion, we suggest that MC4-R activity may not be regulated by changes in agonist (
alpha-MSH
) but by changes in the antagonist (
AGRP
) availability, which may modulate background activation of the receptor by tonic
alpha-MSH
release.
AGRP
may be an important modulator of feeding behaviour.
...
PMID:Changes in hypothalamic agouti-related protein (AGRP), but not alpha-MSH or pro-opiomelanocortin concentrations in dietary-obese and food-restricted rats. 1032 27
Agouti-related protein
(
AGRP
) is a recently discovered orexigenic neuropeptide that inhibits the binding and action of
alpha-melanocyte-stimulating hormone
derived from proopiomelanocortin (POMC) at the melanocortin 3 receptor (MC3R) and melanocortin 4 receptor (MC4R) and has been proposed to function primarily as an endogenous melanocortin antagonist. To better understand the interplay between the
AGRP
and melanocortin signaling systems, we compared their nerve fiber distributions with each other by immunohistochemistry and their perikarya distribution with MC3R and MC4R by double in situ hybridization. Although deriving from distinct cell groups,
AGRP
and melanocortin terminals project to identical brain areas. Both
AGRP
and melanocortin neurons selectively express the MC3R, which provides a neuroanatomical basis for a dual-input circuit with biological amplification and feedback inhibition. These studies highlight a broader complexity in POMC-mediated behavior in the brain.
...
PMID:Anatomy of an endogenous antagonist: relationship between Agouti-related protein and proopiomelanocortin in brain. 1047 19
Agouti protein and
agouti-related protein
(
AGRP
) antagonize
alpha-melanocyte-stimulating hormone
that binds to and activates the melanocortin-4 receptor (MC4-R) in the hypothalamus, thereby stimulating food intake. Melanin-concentrating hormone (MCH) and orexin are orexigenic peptides that specifically are synthesized in the lateral hypothalamus. MCH gene expression was augmented in A(y)/a (agouti) mice which overexpress agouti protein, but orexin mRNA was not.
AGRP
administered intracerebroventricularly into wild-type rats augmented MCH but not orexin gene expression. Also, SHU9119, a peptidergic antagonist of MC4-R, increased only MCH mRNA. These findings indicate that interruption of signaling at MC4-R activates the MCH but not the orexin gene. The biosyntheses of MCH and orexin are regulated through different pathways.
...
PMID:Differential regulation of melanin-concentrating hormone and orexin genes in the agouti-related protein/melanocortin-4 receptor system. 1065 18
The hypothalamic arcuate nucleus has an essential role in mediating the homeostatic responses of the thyroid axis to fasting by altering the sensitivity of prothyrotropin-releasing hormone (pro-TRH) gene expression in the paraventricular nucleus (PVN) to feedback regulation by thyroid hormone. Because
agouti-related protein
(
AGRP
), a leptin-regulated, arcuate nucleus-derived peptide with
alpha-MSH
antagonist activity, is contained in axon terminals that terminate on TRH neurons in the PVN, we raised the possibility that
alpha-MSH
may also participate in the mechanism by which leptin influences pro-TRH gene expression. By double-labeling immunocytochemistry,
alpha-MSH
-IR axon varicosities were juxtaposed to approximately 70% of pro-TRH neurons in the anterior and periventricular parvocellular subdivisions of the PVN and to 34% of pro-TRH neurons in the medial parvocellular subdivision, establishing synaptic contacts both on the cell soma and dendrites. All pro-TRH neurons receiving contacts by
alpha-MSH
-containing fibers also were innervated by axons containing
AGRP
. The intracerebroventricular infusion of 300 ng of
alpha-MSH
every 6 hr for 3 d prevented fasting-induced suppression of pro-TRH in the PVN but had no effect on
AGRP
mRNA in the arcuate nucleus.
alpha-MSH
also increased circulating levels of free thyroxine (T4) 2.5-fold over the levels in fasted controls, but free T4 did not reach the levels in fed controls. These data suggest that
alpha-MSH
has an important role in the activation of pro-TRH gene expression in hypophysiotropic neurons via either a mono- and/or multisynaptic pathway to the PVN, but factors in addition to
alpha-MSH
also contribute to the mechanism by which leptin administration restores thyroid hormone levels to normal in fasted animals.
...
PMID:alpha-Melanocyte-stimulating hormone is contained in nerve terminals innervating thyrotropin-releasing hormone-synthesizing neurons in the hypothalamic paraventricular nucleus and prevents fasting-induced suppression of prothyrotropin-releasing hormone gene expression. 1066 44
We have examined the regulation of the orexigenic neurotransmitter, NPY, in hypothalamic slices of rat brain to discover whether the leptin or melanocortin receptor-4 (MCR-4) agonists, which act as satiety signals, can influence the release of this neurotransmitter. Basal and potassium-stimulated NPY release from hypothalamic slices was not significantly altered by the addition of recombinant murine leptin. However, the melanocortin-4 agonists,
alpha-MSH
and MT-II, significantly inhibited potassium-stimulated NPY release (p < 0.01) without significantly altering basal NPY release. However, the MCR-4 antagonist,
agouti-related protein
, did not significantly alter either basal or stimulated NPY release. In conclusion, hypothalamic NPY release can be attenuated by MCR-4 agonists, but not by leptin, suggesting that the activation of MCR-4 receptors leading to satiety can also further inhibit food intake through an inhibition of orexigenic NPYergic activity.
...
PMID:Regulation of neuropeptide Y release from hypothalamic slices by melanocortin-4 agonists and leptin. 1070 18
Agouti protein and
Agouti-related protein
(
Agrp
) are paracrine signaling molecules that act by antagonizing the effects of melanocortins, and several alternatives have been proposed to explain their mechanisms of action. Genetic crosses in a sensitized background uncover a phenotypic difference between overexpression of Agouti and loss of Mc1r function, demonstrate that a functional Mc1r is required for the pigmentary effects of Agouti, and suggest that Agouti protein can act as an agonist of the Mc1r in a way that differs from
alpha-MSH
stimulation. In vitro, Agouti protein inhibits melanocortin action by two mechanisms: competitive antagonism that depends on the carboxyterminus of the protein, and downregulation of melanocortin receptor signaling that depends on the aminoterminus. Our findings provide evidence of a novel signaling mechanism whereby
alpha-MSH
and Agouti protein function as independent ligands that inhibit each other's binding and transduce opposite signals through a single receptor.
...
PMID:Molecular pharmacology of Agouti protein in vitro and in vivo. 1081 47
1
2
3
4
5
6
7
8
9
10
Next >>